Current use and acceptability of novel diagnostic tests for active tuberculosis : a worldwide survey by Amicosante, Massimo et al.
ISSN 1806-3713© 2017 Sociedade Brasileira de Pneumologia e Tisiologia
http://dx.doi.org/10.1590/S1806-37562017000000219
ABSTRACT
Objective: To determine the current use and potential acceptance (by tuberculosis 
experts worldwide) of novel rapid tests for the diagnosis of tuberculosis that are in line 
with World Health Organization target product profiles. Methods: A multilingual survey 
was disseminated online between July and November of 2016. Results: A total of 723 
individuals from 114 countries responded to the survey. Smear microscopy was the most 
commonly used rapid tuberculosis test (available to 90.9% of the respondents), followed 
by molecular assays (available to 70.7%). Only a small proportion of the respondents 
in middle- and low-income countries had access to interferon-gamma-release assays. 
Serological and lateral flow immunoassays were used by more than a quarter (25.4%) 
of the respondents. Among the respondents who had access to molecular tests, 46.7% 
were using the Xpert assay overall, that proportion being higher in lower middle-income 
countries (55.6%) and low-income countries (76.6%). The data also suggest that there 
was some alignment of pricing for molecular assays. Respondents stated they would 
accept novel rapid tuberculosis tests if available, including molecular assays (acceptable 
to 86.0%) or biomarker-based serological assays (acceptable to 81.7%). Simple 
biomarker-based assays were more commonly deemed acceptable in middle- and low-
income countries. Conclusions: Second-generation molecular assays have become 
more widely available in high- and low-resource settings. However, the development 
of novel rapid tuberculosis tests continues to be considered important by tuberculosis 
experts. Our data also underscore the need for additional training and education of end 
users. 
Keywords: Tuberculosis/diagnosis; Surveys and questionnaires; Income; Mycobacterium 
tuberculosis/isolation & purification; Molecular diagnostic techniques/methods; Serologic 
tests/methods.
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INTRODUCTION
Tuberculosis continues to be one of the most prevalent human infections worldwide, 
the World Health Organization (WHO) reporting that an estimated 10.4 million new 
tuberculosis cases occurred in 2015.(1) In approximately one third of those cases, 
the affected individuals are sputum smear-positive (i.e., have active tuberculosis) 
and could therefore transmit the disease.(1) A core aspect of tuberculosis control 
is the rapid identification and effective treatment of individuals transmitting the 
Mycobacterium tuberculosis complex, the causative agent of tuberculosis.(1-8) However, 
in most settings, more than half of all active tuberculosis cases are not confirmed 
through laboratory testing or the diagnosis is delayed because reliable diagnostic 
tools are not available.(1,3,8)
The most common microbiological test to detect M. tuberculosis is microscopic 
examination of sputum or other clinical material stained for AFB, commonly referred 
to as smear microscopy,(9) in which a positive result is defined as 5,000-10,000 
stained bacilli/mL. Therefore, its sensitivity is variable, depending on several 
factors, and can be as low as 20-30% in some settings.(9) In contrast, culture for 
M. tuberculosis, which is still considered the gold standard, can detect positivity on 
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the basis of only 10-100 viable bacilli/mL of specimen, 
thus identifying M. tuberculosis in more than 80% of 
active tuberculosis cases, with a specificity greater 
than 98%. However, liquid cultures can take two to 
four weeks to produce a positive result and, due to 
the growth characteristics of M. tuberculosis, solid 
cultures can take up to eight weeks.(9)
Rapid M. tuberculosis culture methods and molecular 
assays could play an important role in hastening the 
diagnosis of tuberculosis and generally have high 
specificity.(10,11) However, the implementation of these 
methods is not possible in all clinical settings.(10-17) In 
addition, although molecular assays for the diagnosis 
of tuberculosis—such as the Xpert MTB-RIF assay for 
the identification of M. tuberculosis and the detection 
of rifampin resistance (hereafter referred to as the 
Xpert assay)—are becoming more widely available, they 
are still quite costly, especially at facilities where their 
use is not supported by external funding sources. (18) 
Serology-based tuberculosis tests potentially have the 
necessary characteristics to overcome these problems. 
They can be performed rapidly at a low cost and could 
be used as point-of-care tests, even in low-resource 
clinical settings.(8,18) However, the commercial serological 
tests for active tuberculosis that are currently available 
have suboptimal sensitivity and specificity,(19) as well 
as low reproducibility.(20) Due to those limitations, 
the WHO does not recommend the use of any of the 
currently available commercial serological tests for 
the diagnosis of tuberculosis.(21)
Based on the considerations above and with the aim of 
improving tuberculosis control worldwide, the WHO has 
recently released a document outlining the indications 
for and desirable characteristics of novel tuberculosis 
tests.(8) That document also defined stringent sensitivity 
and specificity criteria for novel rapid diagnostic tests 
for tuberculosis, known as target product profiles 
(TPPs).(8) There are four such TPPs, three of which 
are focused on the rapid identification of tuberculosis 
cases(8,22): a triage test and a biomarker-based test 
(both suitable for point-of-care use); and a rapid 
sputum-based test for detecting M. tuberculosis at the 
microscopy-center level. Although the target sensitivity 
level varies among these test types, depending on the 
form of tuberculosis, it is estimated to be > 90% for 
all three.(22) Similarly (with the exception of the triage 
screening test), the target specificity is quite high, ideally 
in excess of 98%.(22) However, an effective novel test 
for tuberculosis might yet encounter further barriers 
to its acceptance and implementation, including costs 
and infrastructure requirements.(17,18,22) Currently, there 
is limited knowledge on the perceptions and attitudes 
of end users toward novel tests for tuberculosis, which 
could represent an additional hurdle for incorporating 
novel assays into the clinical diagnostic routine. This 
study aimed to determine the current use of existing 
tuberculosis tests, as well as the acceptability of 
future tuberculosis tests, among experts involved in 
tuberculosis diagnostics worldwide.
METHODS
Survey design and data collection
The survey was based on a structured questionnaire, 
designed to elicit feedback, that included a total of 
52 questions, organized into 18 sections: section 1, 
General expertise; section 2, Specific expertise in 
tuberculosis field; section 3, Diagnostic tests in current 
use; sections 4-9, Previous experience with diagnostic 
tests for tuberculosis; sections 10-16, Acceptability 
of novel diagnostic tests for tuberculosis; section 17, 
Accepted performance characteristics of novel diagnostic 
tests for tuberculosis; and section 18, Current price 
of the diagnostic tests and potential acceptability of 
pricing for novel tests. Participation in the survey 
was voluntary. Data were collected anonymously, no 
personal data, except for respondent ages or electronic 
tracking (Internet protocol address or other encoding 
identification) of the survey submission data, being 
recorded. Respondents were aware that they were 
participating in research and that the results would be 
published. Respondents were given the opportunity to 
provide their e-mail address in order to be informed 
of the project results toward the end of the survey. In 
addition, respondents were given the opportunity to 
provide their name and institution at the end of the 
survey in the event that they wished to be named as 
a project collaborator in the resulting publications. 
According to the current standards set by European 
Directive 2001/20/EC and their implementation in 
national regulations (e.g., UK National Research 
Ethics Service regulations, Governance Arrangements 
for Research Ethics Committees, paragraph 2.3.13), 
research ethics committee review is not required for 
research involving healthcare staff recruited as research 
participants, by virtue of their professional role. 
To maximize its accessibility to tuberculosis 
experts worldwide, the questionnaire was offered 
in English, Spanish, and French. The multilingual 
questionnaires were accessible online on a Google 
platform for a 4-month period extending from 16 July 
2016 to 16 November 2016. The English-language 
version of the survey instrument is available 
online (https://docs.google.com/forms/d/188ZEQ-
juNaYeKlIEzMBzGwhzSuHm00loTcf0m_wHths/
edit?usp=sharing). The survey links were distributed, 
by e-mail, to various groups of tuberculosis experts, 
including the tuberculosis experts registered with 
the Global Laboratory Initiative of the WHO (via its 
“listserv” mailing list); the Mycobacteriology Working 
Group of the Italian Society of Clinical Microbiology; the 
European Society of Mycobacteriology; the Paediatric 
Tuberculosis Network European Trials Group; and the 
laboratory specialists of the Tuberculosis Network 
European Trialsgroup Clinical Research Collaboration.
This study was conducted within the framework 
established jointly by the Latin-American Thoracic 
Association and European Respiratory Society. It was 
supported by the Brazilian Thoracic Society and guided 
by the tenets of the Latin-American Thoracic Association/
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European Respiratory Society SinTB project, which is 
focused on eliminating tuberculosis in Latin America.
Statistical analysis, primary data 
stratification, and characteristics of the 
survey population
Data from individual language databases were 
pooled into a single file for the purpose of analysis. The 
information provided for the entry “Country of work” 
was used in order to define the WHO region, as well 
as the World Bank classification and stratification of 
the country by its 2015 gross national income (GNI) 
per capita, according to the Atlas method calculation 
(in US dollars: http://data.worldbank.org/indicator/
NY.GNP.PCAP.CD?order=wbapi_data_value_2014 ± 
wbapi_data_value ± wbapi_data_value-last&sort=desc). 
Those two parameters were used for the primary 
stratification of the survey data. Each country 
was classified as low-income (GNI per capita ≤ 
US$1,025); lower middle-income (GNI per capita of 
US$1,026–4,035); upper middle-income (GNI per 
capita of US$4,036–12,475); or high-income (GNI 
per capita ≥ US$12,476). Data were available for all 
entry countries, although not for Palestine, which was 
therefore not included in any of the sub-stratification 
analyses.
Analyses were carried out with the SPSS Statistics 
software package for Windows, version 19.0 (SPSS 
Italia SRL, Bologna, Italy), Prism 6 (Graphpad Software, 
San Diego, CA, USA), and the Real Statistics add-in 
for Excel (available at http://www.real-statistics.
com/). Continuous variables are expressed as mean 
± standard deviation, whereas dichotomous and 
categorical variables are expressed as absolute and 
relative frequencies. For the comparison of continuous 
variables among groups, ANOVA was used, whereas the 
chi-square test and logistic regression were used for the 
comparison of dichotomous and categorical variables. 
After multiple comparisons, Bonferroni correction was 
used if required. Values of p ≤ 0.05 after Bonferroni 
correction were considered statistically significant.
RESULTS
A total of 723 respondents from 114 countries and 
territories participated in the survey. Figure 1 shows 
the geographical location of the survey respondents. 
For 15 countries—including most of the countries on the 
WHO list of high tuberculosis burden countries(1)—there 
were 10 or more respondents; for 27 countries, there 
was only one respondent. Table 1 summarizes the 
characteristics of the respondents, including age, level 
of education, place of work, work experience, and 
expertise. The three largest groups of professional 
respondents included those with expertise in infectious 
diseases, those with expertise in pulmonology, and those 
with expertise in microbiology, collectively comprising 
nearly two thirds (64.45%) of the study population, 
with no significant differences among respondents 
in terms of their background in clinical or laboratory 
work (p = 0.1075). 
In agreement with the general global trend reported by 
the United Nations,(23) the age of the survey respondents 
was significantly lower in low-income countries than in 
high-income and upper middle-income countries (p < 
0.0001 for both comparisons). As can be seen in Table 
1, respondent ages were also lower in the lower middle-
income countries than in the high-income countries 
(p = 0.0003). In addition, the survey respondents in 
high-income countries included a significantly higher 
Legend
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Figure 1. Geographic distribution of the survey respondents, by country. A graded color scale (bottom left) indicates 
the density of respondents in each country.
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Table 1. Characteristics of the survey respondents.a
Variable Income level of the countries (World Bank 
classification)
Total p*
High Upper 
middle
Lower 
middle
Low
(n = 191) (n = 263) (n = 172) (n = 96) (n = 723b)
Proportional distribution, % 26.4 36.4 23.8 13.3 100.0 < 0.00001
Age (years), mean ± SD 48.2 ± 9.9 46.3 ± 11.0 44.3 ± 10.3 42.2 ± 10.2 45.8 ± 10.6 < 0.00001
Age range (years) < 0.00001
21-30 5 (2.6) 16 (6.1) 14 (8.1) 7 (7.3) 42 (5.8)
31-40 38 (19.9) 77 (29.3) 56 (32.6) 43 (44.8) 215b (29.7)
41-50 74 (38.7) 63 (24.0) 54 (31.4) 27 (28.1) 218 (30.2)
51-60 54 (28.3) 81 (30.8) 39 (22.7) 15 (15.6) 189 (26.1)
≥ 61 20 (9.4) 26 (9.8) 9 (5.1) 4 (4.1) 54 (8.2)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
Highest level of education < 0.00001
High school 2 (1.0) 2 (0.8) 2 (1.2) 1 (1.0) 7 (1.0)
Undergraduate degree 24 (12.6) 79 (30.0) 37 (21.5) 22 (22.9) 163b (22.5)
Masters degree 35 (18.3) 76 (28.9) 69 (40.1) 49 (51.0) 229 (31.7)
Doctorate 85 (44.5) 65 (24.7) 42 (24.4) 19 (19.8) 211 (29.2)
Postgraduate work 45 (23.6) 41 (15.6) 22 (12.8) 5 (5.2) 113 (15.6)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
Experience in tuberculosis < 0.00001
1-5 years 25 (13.1) 48 (18.3) 30 (17.4) 23 (24.0) 127b (17.6)
6-9 years 42 (22.0) 53 (20.2) 51 (29.7) 28 (29.2) 174 (24.1)
10-20 years 83 (43.5) 75 (28.5) 62 (36.0) 32 (33.3) 252 (34.9)
> 20 years 41 (21.5) 87 (33.1) 29 (16.9) 13 (13.5) 170 (23.5)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
Main employer < 0.00001
Public health 94 (49.2) 163 (62.0) 82 (47.7) 51 (53.1) 391b (54.1)
Academic institution 54 (28.3) 44 (16.7) 30 (17.4) 15 (15.6) 143 (19.8)
Other publicly funded institute 19 (9.9) 23 (8.7) 15 (8.7) 14 (14.6) 71 (9.8)
Private healthcare facility 5 (2.6) 24 (9.1) 12 (7.0) 2 (2.1) 43 (5.9)
Industry 5 (2.6) 2 (0.8) 1 (0.6) 1 (1.0) 9 (1.2)
Other private concern 14 (7.3) 7 (2.7) 32 (18.6) 13 (13.5) 66 (9.1)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
Main focus in tuberculosis < 0.00001
Adult 78 (40.8) 128 (48.7) 42 (24.4) 22 (22.9) 271 (37.5)
Pediatric 30 (15.7) 3 (1.1) 20 (11.6) 4 (4.2) 57 (7.9)
Adult and pediatric 83 (43.5) 129 (49.0) 107 (62.2) 69 (71.9) 388 (53.7)
No answer provided 0 (0.0) 3 (1.1) 3 (1.7) 1 (1.0) 7 (1.0)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
Main area of expertise < 0.00001
Infectious diseases 58 (30.4) 57 (21.7) 35 (20.3) 32 (33.3) 183b (25.3)
Pulmonology 39 (20.4) 72 (27.4) 33 (19.2) 11 (11.5) 155 (21.4)
General medicine (adult) 1 (0.5) 34 (12.9) 11 (6.4) 12 (12.5) 58 (8.0)
Pediatrics 10 (5.2) 2 (0.8) 7 (4.1) 3 (3.1) 22 (3.0)
Microbiology 43 (22.5) 44 (16.7) 30 (17.4) 11 (11.5) 128 (17.7)
Immunology 10 (5.2) 12 (4.6) 7 (4.1) 3 (3.1) 32 (4.4)
Laboratory medicine 10 (5.2) 8 (3.0) 19 (11.0) 12 (12.5) 49 (6.8)
Basic science 4 (2.1) 9 (3.4) 5 (2.9) 0 (0.0) 18 (2.5)
Other 16 (8.4) 25 (9.5) 25 (14.5) 12 (12.5) 78 (10.8)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
aValues expressed as n (%), except where otherwise indicated. bIncludes one respondent working in a country 
that could not be classified according to the World Bank classification. *ANOVA or chi-square test, with Bonferroni 
correction.
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proportion of respondents with graduate degrees 
and professorships (p < 0.0001 for all comparisons), 
although no such differences were detected among 
the other subgroups (Table 1). The distribution of 
the respondents by their years of experience in the 
area of tuberculosis was comparable between lower 
middle-income and low-income countries (p = 0.59), 
whereas the number of respondents with long-term 
experience in tuberculosis was significantly higher in 
high-income and upper middle-income countries than 
in lower middle-income and low-income countries (p 
< 0.0001 for all comparisons), as shown in Table 1. 
Stratification of the survey data by GNI per capita (the 
World Bank classification) allowed an assessment of the 
differences between countries with different tuberculosis 
testing needs, as well as different tuberculosis incidence 
rates. The main differences observed regarding age 
and expertise were considered for correction in the 
subsequent analyses.
Laboratory throughput and current tests for 
the diagnosis of active tuberculosis
Of the 723 survey respondents, 690 (95.4%) had 
access to or were regularly performing laboratory 
tests for tuberculosis. Table 2 shows the number 
of diagnostic tests for tuberculosis performed per 
year and the range of tests to which the survey 
respondents stated they had access. More than half 
of the survey respondents had access to laboratory 
facilities performing more than 1,000 diagnostic tests 
for tuberculosis per year. As expected, the proportion 
of respondents with access to a laboratory performing 
more than 5,000 diagnostic tests for tuberculosis 
per year was higher among respondents working in 
low-income countries than among those working in 
high-income and upper middle-income countries (p < 
0.05 for both comparisons). 
Among assays for the diagnosis of active tuberculosis, 
AFB staining was the most widely available test (available 
to 90.8% of the survey respondents), followed by 
solid culture (73.7%). In high-income countries, 
liquid culture was more widely available than was 
solid culture (Table 2). As expected, molecular assays 
were more widely available in high-income countries 
than in other countries, comparisons being made for 
commercial molecular assays (p < 0.00001 for all 
comparisons), in-house molecular assays (p < 0.02 
for all comparisons), and any molecular assay (p < 
0.00001 for all comparisons). However, the data show 
that more than two thirds of the respondents in low- and 
lower middle-income countries had access to molecular 
assays (Table 2). This contrasts with the availability of 
interferon-gamma release assays (IGRAs) among survey 
respondents, which was strongly correlated with the 
country income classification (p = 0.0026). We found 
that IGRAs were more widely available in laboratories 
located in high-income countries than in those located 
in other countries (p < 0.00001 for all comparisons).
Finally, although the use of the currently available 
commercial serological tests for tuberculosis has been 
strongly discouraged by the WHO since 2010,(21) the 
survey data suggest that they remain widely available 
in tuberculosis laboratories. More than a quarter of 
the survey respondents stated that either ELISA-based 
serological tests or lateral flow immunoassays were in 
use in their laboratories, with no significant differences 
between countries by income (p = 0.0723 for all 
comparisons), as shown in Table 2. 
Prices of rapid diagnostic tests for 
tuberculosis
In the multivariate analysis of the responses (Table 
3), the prices of rapid tuberculosis assays were found 
to be associated with the availability of commercial 
molecular assays and with the availability of AFB staining 
only, regardless of the country income classification (p 
< 0.002 for all comparisons). In contrast, the type of 
employing institution, number of tests performed per 
year, years of experience in the area of tuberculosis, 
level of education, and decision-making capacity were 
Table 1. Continued...
Variable Income level of the countries (World Bank 
classification)
Total p*
High Upper 
middle
Lower 
middle
Low
(n = 191) (n = 263) (n = 172) (n = 96) (n = 723b)
Area of interest in tuberculosis 
(multiple answers allowed)
0.0542
Clinical 126 (66.0) 184 (70.0) 93 (54.1) 54 (56.3) 458b (63.3)
Laboratory 89 (46.6) 133 (50.6) 84 (48.8) 45 (46.9) 351 (48.5)
Research 105 (55.0) 146 (55.5) 98 (57.0) 71 (74.0) 420 (58.1)
Policy Maker 25 (13.1) 53 (20.2) 40 (23.3) 36 (37.5) 154 (21.3)
Test Producer 12 (6.3) 34 (12.9) 8 (4.7) 6 (6.3) 60 (8.3)
Other Industry 1 (0.5) 2 (0.8) 2 (1.2) 3 (3.1) 8 (1.1)
Other 11 (5.8) 11 (4.2) 10 (5.8) 9 (9.4) 41 (5.7)
Total 191 (100.0) 263 (100.0) 172 (100.0) 96 (100.0) 723b (100.0)
aValues expressed as n (%), except where otherwise indicated. bIncludes one respondent working in a country 
that could not be classified according to the World Bank classification. *ANOVA or chi-square test, with Bonferroni 
correction.
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not associated with the stated prices for the tests (p 
> 0.09 for all comparisons, data not shown).
As can be seen in Table 3, more than a third of the 
survey respondents did not know the current prices 
(i.e., the costs, excluding labor and overhead) of rapid 
tests for the diagnosis of tuberculosis. The prices 
stated by the respondents working in high-income 
countries were generally higher than the prices stated 
by those working in the other countries (p < 0.0055 
for all comparisons). Similarly, the stated prices were 
higher in upper middle-income countries than in lower 
middle- and low-income countries (p < 0.00001 for 
all comparisons). As expected, the use of commercial 
molecular assays represented the main reason for high 
prices of tests for the diagnosis of active tuberculosis. 
As can be seen in Table 3, the survey respondents who 
had access only to AFB staining stated lower prices 
than did those who had access to AFB staining plus 
molecular assays and those who had access only to 
molecular assays (p < 0.05 for all comparisons). 
Impact of the Xpert assay on the availability 
and pricing of molecular tests
For survey respondents working in lower middle- and 
low-income countries where molecular assays were 
available, the price range most often indicated for rapid 
tests was US$ 10-20 (Table 3). This is in accordance 
with the pricing negotiated by the Foundation for 
Innovative New Diagnostics for the Xpert assay in 
low-resource settings. Therefore, we attempted to 
ascertain whether access to that specific test plays a 
significant role in determining the rapid test price range 
indicated in lower middle- and low-income countries. 
Among 413 survey respondents who reported having 
access to commercial molecular assays, 193 (46.7%) 
reported using the Xpert assay alone or in combination 
with other molecular assays for the diagnosis of 
tuberculosis. As shown in Table 4, the proportions of 
respondents using Xpert assays were higher than those 
of respondents using other molecular assays in the 
lower middle- and low-income countries, and that ratio 
was lower in the high-income and upper middle-income 
countries (p < 0.05 for all comparisons).
Table 5 shows the reported prices for rapid tests 
among molecular assay users, stratified by the use 
of Xpert assays. Apart from the differences observed 
among countries by income, no significant differences 
were observed between the prices reported for the 
Xpert assay and those reported for other molecular 
assays in each income subgroup. This suggests that 
manufacturers of other commercial molecular assays 
have adjusted the pricing of their assays to match 
that of the Xpert assay. Table 6 shows the level of 
experience of the survey respondents with molecular 
Table 2. Diagnostic tuberculosis tests in current use and total annual throughput as stated by the respondents.a
Variable Total Income level of the countries 
(World Bank classification)
p*
High Upper 
middle
Lower 
middle
Low
(n = 690b) (n = 179) (n = 257) (n = 162) (n = 91)
Proportional distribution, % 25.94 37.25 23.48 13.19
Tuberculosis tests per year 0.023
< 100 70 (10.14) 25 (13.97) 28 (10.89) 13 (8.02) 3 (3.30)
100-1,000 175 (25.36) 36 (20.11) 77 (29.96) 41 (25.31) 21 (23.08)
1,000-5,000 187 (27.10) 56 (31.28) 68 (26.46) 42 (25.93) 21 (23.08)
> 5,000 196 (28.41) 49 (27.37) 64 (24.90) 52 (32.10) 31 (34.07)
Not known 62 (8.99) 13 (7.26) 20 (7.78) 14 (8.64) 15 (16.48)
Type of test (multiple answers) < 0.00001
AFB staining 627c (90.87) 158 (88.27) 228 (88.72) 155 (95.68) 85 (93.41)
Solid culture 509c (73.77) 142 (79.33) 187 (72.76) 111 (68.52) 68 (74.73)
Liquid culture 468c (67.83) 151 (84.36) 155 (60.31) 103 (63.58) 58 (63.74)
First-line drug susceptibility 500 (72.46) 140 (78.21) 174 (67.70) 121 (74.69) 65 (71.43)
Second-line drug susceptibility 317 (45.94) 102 (56.98) 99 (38.52) 78 (48.15) 38 (41.76)
“In-house” molecular assay 193 (27.97) 70 (39.11) 58 (22.57) 44 (27.16) 21 (23.08)
Commercial molecular assay 413 (59.86) 145 (81.01) 131 (50.97) 90 (55.56) 47 (51.65)
IGRA 264 (38.26) 144 (80.45) 76 (29.57) 37 (22.84) 7 (7.69)
ELISA-based assay (serology) 124 (17.97) 31 (17.32) 63 (24.51) 18 (11.11) 12 (13.19)
LFIA 75 (10.87) 26 (14.53) 26 (10.12) 12 (7.41) 11 (12.09)
Other 20 (2.90) 8 (4.47) 9 (3.50) 3 (1.85) 0 (0.00)
Any serological test (ELISA+LFIA) 175 (25.36) 50 (27.93) 76 (29.57) 27 (16.67) 22 (24.18) 0.0723
Any molecular assay 488 (70.72) 157 (87.71) 154 (59.92) 115 (70.99) 62 (68.13) < 0.00001
IGRA: interferon-gamma release assay; and LFIA: lateral flow immunoassay. aValues expressed as n (%), except 
where otherwise indicated. bIncludes data only from respondents who stated that they were performing tests. 
cIncludes one respondent working in a country that could not be classified according to the World Bank classification. 
*Chi-square test, with Bonferroni correction.
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tests, stratified by use of the Xpert assay and other 
molecular assays.
Acceptability of novel rapid diagnostic 
tests for tuberculosis
The level of acceptability (an indirect indicator of the 
need for novel rapid diagnostic tests for tuberculosis) 
was determined for two different prototype assays: a 
novel molecular assay in line with the WHO TPP for a 
rapid sputum-based test for detecting M. tuberculosis; 
and a novel serological test in line with the WHO TPP 
for a biomarker-based triage test. Table 7 summarizes 
the results regarding the acceptability of the two 
assays among the survey respondents. More than 
80% of the respondents would accept either novel 
test, provided that certain criteria were met, and there 
was no statistical difference between the two tests in 
terms of their acceptability (p = 0.084). 
With regard to novel molecular assays, responses 
regarding general acceptability did not differ significantly 
among countries stratified by World Bank classification 
income level (p = 0.0825). The level of acceptance was 
significantly associated with a higher level of respondent 
education, defined as a doctorate or professorship 
(p < 0.002, data not shown), although not with the 
respondent having a decision-making role, respondent 
age, or respondent years of experience in the area 
of tuberculosis (p > 0.05 for all comparisons). It is 
noteworthy that the conditional acceptance based on 
validation differed between country types by income 
(p < 0.0025): survey respondents working in high-
income countries were most likely to accept a test still 
undergoing validation (p < 0.05 for all comparisons), as 
shown in Table 7. Acceptance of a molecular assay still 
undergoing validation was positively associated with a 
higher level of respondent education (p < 0.003, data 
not shown) and expertise in immunology (p < 0.002, 
data not shown), whereas it showed no association 
with the respondent having a decision-making role, 
respondent age, or respondent years of experience in 
the area of tuberculosis (p > 0.05, data not shown). 
In contrast to the responses regarding the general 
acceptability of molecular assays, those regarding that 
of a novel serological assay differed significantly among 
Table 3. Price ranges (in US$), declared by the survey respondents, of rapid tests for the diagnosis of active tuberculosis, 
excluding labor and overhead.a
Parameter Total Income level of the countries (World Bank classification) p
High Upper middle Lower middle Low
Price range (US$) Users of AFB staining only
1-10 123 (25.68) 16 (14.04) 30 (17.44) 47 (36.43) 30 (46.88) < 0.00001
11-20 146 (30.48) 17 (14.91) 51 (29.65) 54 (41.86) 24 (37.50)
20-30 59 (12.32) 23 (20.18) 22 (12.79) 9 (6.98) 5 (7.81)
30-50 57 (11.90) 25 (21.93) 18 (10.47) 11 (8.53) 3 (4.69)
> 50 94 (19.62) 33 (28.95) 51 (29.65) 8 (6.20) 2 (3.13)
Subtotal 479 114 172 129 64
Not known 244b (33.75) 77 (40.31) 91 (34.60) 43 (25.00) 32 (33.33)
Total 723b 191 263 172 96
Price range (US$) Users of molecular assays only
1-10 64 (20.71) 9 (9.57) 14 (13.46) 28 (35.90) 13 (39.39) < 0.00001
11-20 99 (32.04) 14 (14.89) 34 (32.69) 36 (46.15) 15 (45.45)
20-30 38 (12.30) 19 (20.21) 13 (12.50) 5 (6.41) 1 (3.03)
30-50 40 (12.94) 20 (21.28) 14 (13.46) 3 (3.85) 3 (9.09)
> 50 68 (22.01) 32 (34.04) 29 (27.88) 6 (7.69) 1 (3.03)
Subtotal 309 94 104 78 33
Not known 104 (25.18) 51 (35.17) 27 (20.61) 12 (13.33) 14(29.79)
Total 413 145 131 90 47
Users of AFB staining and commercial molecular assays
Price range (US$) Total AFB staining 
plus commercial 
molecular assays
AFB staining only Commercial 
molecular assays 
only
1-10 113 (25.11) 64 (21.84) 49 (34.75) 0 (0.00) 0.0262
11-20 134 (29.78) 91 (31.06) 35 (24.82) 8 (50.00)
20-30 56 (12.44) 35 (11.95) 18 (12.77) 3 (18.75)
30-50 55 (12.22) 37 (12.63) 15 (10.64) 3 (18.75)
> 50 92 (20.44) 66 (22.53) 24 (17.02) 2 (12.50)
Subtotal 450 293 141 16
Not known 202 (30.98) 95 (24.48) 98 (41.00) 9 (36.00)
Total 652 388 239 25
aValues expressed as n (%), except where otherwise indicated. bIncludes one respondent working in a country that 
could not be classified according to the World Bank classification.
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countries by income level (p = 0.0283). As can be seen 
in Table 7, fewer than three quarters of respondents 
working in high-income countries stated that such a test 
would be acceptable, which was significantly lower than 
that found for respondents working in other countries 
(p < 0.05 for all comparisons). Additional analyses 
revealed no association between acceptability and 
the level of education of the respondent, respondent 
age, and respondent years of experience in the area 
of tuberculosis (p > 0.05 for all comparisons, data not 
shown), whereas the respondent having a decision-
making role showed borderline significance (p = 0.05 
for all comparisons, data not shown). 
Acceptability of novel rapid diagnostic 
tests for tuberculosis in relation to their 
performance characteristics
Although more than 80% of the 723 survey 
respondents indicated general acceptance of a novel 
rapid diagnostic test for tuberculosis—622 (86.0%) 
indicating acceptance of a molecular test and 591 
(81.7%) indicating acceptance of a serological test—391 
(54.1%) indicated that their acceptance depended on 
test accuracy. The results regarding the acceptability 
of novel tuberculosis tests based on their performance 
characteristics are summarized in Table 8. Nearly two 
thirds of the respondents indicated that they would 
expect a minimum sensitivity of > 90% (i.e., within 
the range of optimal sensitivity for the WHO TPPs 
for biomarker-based tests and rapid sputum-based 
tests). Fewer than 7% of the respondents indicated 
that they would be satisfied with a test sensitivity ≤ 
80%. The expected sensitivity stated by respondents 
was not found to be associated with variables related 
to the respondent (years of experience in the area 
of tuberculosis, age, level of education, having a 
decision-making role, main area of expertise, and field 
of interest within the area of tuberculosis) or with the 
country income level (p > 0.05 for all comparisons, 
data not shown). 
Only 10.6% of the respondents stated that a specificity 
of 80-90%, the target specificity level stated in the 
WHO TPP for a triage test for active tuberculosis, 
would be acceptable. More than two thirds of the 
respondents stated that a novel test should have 
a minimum specificity of 95%. As with sensitivity, 
the level of specificity expected was not found to be 
associated with variables related to the respondent 
Table 4. Declared use of molecular assays among the survey respondents.a
Test used Total Income level of the countries 
(World Bank classification)
p
High Upper middle Lower middle Low
Xpert MTB/RIF 193 (46.73) 52 (35.86) 55 (41.98) 50 (55.56) 36 (76.60) < 0.00001
Other molecular assays 220 (53.27) 92 (63.45) 76 (58.02) 41 (45.56) 11 (23.40)
Total 413 145 131 90 47
Xpert MTB/RIF: rapid molecular assay for the identification of Mycobacterium tuberculosis and the detection of 
rifampin resistance. aValues expressed as n (%), except where otherwise indicated.
Table 5. Rapid tuberculosis test prices, as reported by the molecular assay users surveyed, stratified by use of the 
Xpert assay and other molecular assays.a
Price range 
(US$)
Total Income level of the countries (World Bank classification)
High Upper middle Lower middle Low
Molecular assay 
use
Molecular assay 
use
Molecular assay 
use
Molecular assay 
use
Molecular assay 
use
Xpert Other Xpert Other Xpert Other Xpert Other Xpert Other
1-10 40
(26.32)
24
(15.29)
5
(12.20)
4
(7.55)
6
(13.33)
8
(13.56)
18
(43.90)
10
(27.03)
11
(44.00)
2
(25.00)
11-20 54
(35.53)
45
(28.66)
7
(17.07)
7
(13.21)
17
(37.78)
17
(28.81)
19
(46.34)
17
(45.95)
11
(44.00)
4
(50.00)
20-30 17
(11.18)
21
(13.38)
10
(24.39)
9
(16.98)
5
(11.11)
8
(13.56)
1
(2.44)
4
(10.81)
1
(4.00)
0
(0.00)
30-50 12
(7.89)
28
(17.83)
6
(14.63)
14
(26.42)
4
(8.89)
10
(16.95)
0
(0.00)
3
(8.11)
2
(8.00)
1
(12.50)
> 50 29
(19.08)
39
(24.84)
13
(31.71)
19
(35.85)
13
(28.89)
16
(27.12)
3
(7.32)
3
(8.11)
0
(0.00)
1
(12.50)
Subtotal 152 157 41 53 45 59 41 37 25 8
p 0.0621 0.5569 0.7336 0.1354 0.3818
Do not know 40
(20.83)
64
(28.96)
12
(22.64)
39
(42.39)
10
(18.18)
17
(22.37)
9
(18.00)
3
(7.50)
9
(26.47)
5
(38.46)
Total 192 221 53 92 55 76 50 40 34 13
Xpert: rapid molecular assay for the identification of Mycobacterium tuberculosis and the detection of rifampin 
resistance. aValues expressed as n (%), except where otherwise indicated.
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(years of experience in the area of tuberculosis, age, 
level of education, having a decision-making role, main 
area of expertise, and field of interest within the area 
of tuberculosis) or with the country income level (p > 
0.05 for all comparisons, data not shown). 
DISCUSSION
Tuberculosis control policies(1,2) are intimately related 
to the availability of effective tests for the diagnosis 
of active tuberculosis and for the identification of 
latent tuberculosis infection. Improved tuberculosis 
diagnostics, together with other interventions, are key 
to reaching the goal of entering the pre-elimination 
phase by 2035 in countries with a low incidence of 
the disease.(2,3,5) In this context, the WHO released 
indications for the TPP for tuberculosis tests in 2014, 
with the specific aim of setting the agenda for the 
development of rapid tests for the diagnosis of active 
tuberculosis.(8) However, policy application and the 
acceptance of novel tests could face additional barriers, 
including the perceptions and needs of tuberculosis 
specialists. 
In this paper, we have reported the results of a large 
global survey on tuberculosis diagnostics, including tests 
in current use and novel tests, establishing end-user 
acceptance based upon performance characteristics, 
the availability of validation data, and pricing, taking 
Table 6. Experience with molecular tests among survey respondents, stratified by use of the Xpert assay and other 
molecular assays.a
Test used Income level of the countries (World Bank classification) p*
High income Upper middle 
income
Lower middle 
income
Low-income
Years of experience with molecular assays
1-10 > 10 1-10 > 10 1-10 > 10 1-10 > 10
Xpert MTB/RIF 23 (46.94) 26 (53.06) 46 (86.79) 7 (13.21) 42 (84.00) 8 (16.00) 30 (88.24) 4  (11.76) < 0.00001
Other molecular 
assays
29 (35.80) 52 (64.20) 45 (66.18) 23 (33.82) 20 (74.07) 7 (25.93) 6  (75.00) 2 (25.00) 0.003
p* 0.2846 0.0742 0.3891 0.3923
aValues expressed as n (%), except where otherwise indicated. *Corrected for respondent age.
Table 7. Acceptability of a novel rapid sputum-based molecular assay and a novel serological assay.a
Acceptability Total Income level of the countries (World Bank 
classification)
p
High Upper 
middle
Lower 
middle
Low
Novel rapid molecular assay  
(prototype of a sputum-based assay)
Not acceptable 38 (5.26) 9 (4.71) 12 (4.56) 7 (4.07) 10 (10.42) 0.0825
Acceptable 622b (86.03) 157 (82.20) 235 (89.35) 153 (88.95) 76 (79.17)
Do not know 63 (8.71) 25 (13.09) 16 (6.08) 12 (6.98) 10 (10.42)
Total 723b 191 263 172 96
Acceptable only if fully validated 355 (57.07) 70 (44.59) 140 (59.57) 101 (66.01) 44 (57.89) 0.0025
Acceptable even if still being 
validatedc
227 (36.50) 78 (49.68) 81 (34.47) 41 (26.80) 27 (35.53)
Acceptable (manufacturer’s 
assurance sufficient)
40b (6.43) 9 (5.73) 14 (5.96) 11 (7.19) 5 (6.58)
Novel serological assay  
(prototype of a biomarker-based triage test)
Not acceptable 61 (8.44) 20 (10.47) 19 (7.22) 17 (9.88) 5 (5.21) 0.0383
Acceptable 591b (81.74) 141 (73.82) 227 (86.31) 140 (81.40) 82 (85.42)
Do not know 71 (9.82) 30 (15.71) 17 (6.46) 15 (8.72) 9 (9.38)
Total 723b 191 263 172 96
Acceptable only if fully validated and 
in line with WHO indications
378b (63.96) 78 (55.32) 144 (63.44) 100 (71.43) 55 (67.07) 0.1250
Acceptable even if still being 
validated,c provided it was developed 
in line with WHO indications
193 (32.66) 59 (41.84) 73 (32.16) 36 (25.71) 25 (30.49)
Acceptable (manufacturer’s 
assurance sufficient)
20 (3.38) 4 (2.84) 10 (4.41) 4 (2.86) 2 (2.44)
aValues expressed as n (%), except where otherwise indicated. bIncludes one respondent working in a country that 
could not be classified according to the World Bank classification. cIf sufficiently independent peer-reviewed data 
are available.
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the WHO TPPs into account. The survey respondents 
comprised 723 tuberculosis specialists from 114 
countries and territories, with good coverage of 
regions with a high incidence of tuberculosis (Figure 
1), and we therefore believe that the data collected 
are representative. To our knowledge, this is the 
largest study to date on the opinions and perceptions 
of the end users of tuberculosis tests regarding novel 
tuberculosis diagnostics. 
Our data show that AFB staining continues to be the 
most widely available test for tuberculosis, more than 
90% of the survey respondents having access to this 
test. However, only three quarters of the respondents 
had access to culture and drug-susceptibility tests 
to properly identify the pathogen and determine 
the resistance pattern by phenotypic assays, which 
are still considered the gold standard. Our data also 
indicate that IGRAs are largely used by professionals 
for the diagnosis of tuberculosis infection mainly in 
high-income countries. Replacing tuberculin skin tests 
with IGRAs in middle- and low-income countries has 
been discouraged by the WHO, because IGRAs are 
technically complex and far more expensive, as well 
as because, despite their higher costs (because IGRAs 
usually also require laboratory technicians trained in 
their use), their performance is comparable to that 
of tuberculin skin tests.(24) Despite their suboptimal 
performance,(24,25) as well as the limitations to their use 
in young children, the elderly, and immunocompromised 
patients,(26-30) IGRAs are still widely used in high-income 
countries. However, tuberculosis pre-elimination and 
elimination policies will require novel tests for the rapid 
identification of individuals infected with tuberculosis 
and of those progressing to active tuberculosis, ideally 
with high sensitivity, high specificity, and low costs.(31)
More than 70% of the survey respondents stated 
that they had access to in-house or commercial 
molecular assays for the diagnosis of tuberculosis. 
In high-income countries, the large majority of 
respondents had access to such molecular assays. 
Even in lower income countries, approximately two 
thirds of the respondents had access to such assays, 
likely as a reflection of the large-scale roll-out of the 
Xpert assay, driven by WHO policy and a preferential 
pricing structure for low resource settings.(10) In 
addition, we found that the introduction of the Xpert 
assay at a subsidized price(10,18,22) resulted in a 
general alignment of molecular assay prices. In fact, 
the prices of first-generation commercial molecular 
assays (e.g., Amplicor and GeneProbe) were in the 
range of US$30-50 per test during the 2000-2008 
period.(32,33) The present survey indicates that the 
current molecular assays are mostly in the US$11-20 
price range, with common geographic pricing policies 
and no significant differences in price ranges between 
the Xpert assay and other molecular assays. A policy 
of sustained support and implementation of efficient 
second-generation assays will likely contribute to 
further increasing access to high-quality diagnostics, 
especially in low-income countries.
Due to the low reproducibility and poor specificity of 
the currently available serological tests for the diagnosis 
of active tuberculosis (lateral flow immunoessays in 
particular),(19,20) the WHO has issued a recommendation 
against their use.(21) It was therefore surprising to find 
that more than a quarter of the survey respondents 
stated that they were currently using such tests. 
This is a cause for concern, because the use of these 
poorly performing tests results not only in significant 
expenditures but also in inappropriate management 
of patients. However, given that serological tests for 
tuberculosis might have some key advantages (including 
short assay times and comparatively low prices), there 
is a need for further research on novel serological tests 
developed in line with the WHO TPPs. It was also of 
note that the clear majority of respondents stated that 
Table 8. Minimum sensitivity and specificity expected by survey respondents for novel tests for the diagnosis of active 
tuberculosis.a
Parameter Total Income level of the countries (World Bank classification) p
High Upper middle Lower middle Low
Expected sensitivity
> 50% 2 (0.51) 0 (0.00) 0 (0.00) 1 (1.35) 1 (2.08) 0.0976
> 60% 4 (1.03) 1 (0.76) 1 (0.74) 0 (0.00) 2 (4.17)
> 70% 21 (5.40) 10 (7.63) 6 (4.41) 2 (2.70) 3 (6.25)
> 80% 104 (26.74) 38 (29.01) 42 (30.88) 19 (25.68) 5 (10.42)
> 90% 243 (62.47) 78 (59.54) 84 (61.76) 48 (64.86) 33 (68.75)
Do not know 15 (3.86) 4 (3.05) 3 (2.21) 4 (5.41) 4 (8.33)
Total 389 131 136 74 48  
Expected specificity
> 99% 99 (25.65) 31 (23.66) 34 (25.37) 23 (31.08) 11 (23.40) 0.2970
> 95% 174 (45.08) 66 (50.38) 57 (42.54) 29 (39.19) 22 (46.81)
> 90% 58 (15.03) 20 (15.27) 25 (18.66) 10 (13.51) 3 (6.38)
> 80% 41 (10.62) 10 (7.63) 16 (11.94) 8 (10.81) 7 (14.89)
Do not know 14 (3.63) 4 (3.05) 2 (1.49) 4 (5.41) 4 (8.51)
Total 386 131 134 74 47  
aValues expressed as n (%), except where otherwise indicated.
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they would find a novel serological assay acceptable, 
as long as sufficient supporting data were available.
The survey results indicate that over 80% of 
tuberculosis specialists are likely to accept a novel 
test for the rapid diagnosis of active tuberculosis if it 
is offered at an affordable price. Our results suggest 
that there is a perceived need for rapid assays that 
are more efficient, as well as that the acceptability 
of such assays is influenced by cost, respondents 
wanting the prices to be lower than those of the 
existing assays. This underscores the fact that, even 
with the preferential pricing that is currently available 
to facilities in low-resource countries, the prices of 
the tests are still perceived as prohibitive by some 
tuberculosis experts. 
Although the WHO developed TPPs for rapid tests 
for the diagnosis of tuberculosis three years ago,(8) 
nearly half of the tuberculosis experts surveyed stated 
they would accept a novel test for the diagnosis of 
tuberculosis even in the absence of robust data on 
test performance (based on assurances from the 
manufacturer alone or on preliminary data obtained 
while the test is still undergoing validation). Our findings 
indicate that, in addition to setting policies, there is a 
need to educate the end users of rapid tests for the 
diagnosis of tuberculosis. 
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